Hasil Pencarian - David R Fogelman

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma

    Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma oleh Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff, Milind Javle

    Diterbitkan 2018-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

    Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma oleh Jane E. Rogers, Jonathan D. Mizrahi, Lianchun Xiao, Chirayu Mohindroo, Rachna T. Shroff, Robert Wolff, Gauri R. Varadhachary, Milind M. Javle, Michael Overman, David R. Fogelman, Kanwal P. S. Raghav, Shubham Pant, Florencia McAllister

    Diterbitkan 2020-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.

    Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. oleh Amir Mehrvarz Sarshekeh, Shailesh Advani, Michael J Overman, Ganiraju Manyam, Bryan K Kee, David R Fogelman, Arvind Dasari, Kanwal Raghav, Eduardo Vilar, Shanequa Manuel, Imad Shureiqi, Robert A Wolff, Keyur P Patel, Raja Luthra, Kenna Shaw, Cathy Eng, Dipen M Maru, Mark J Routbort, Funda Meric-Bernstam, Scott Kopetz

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients

    Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients oleh Chirayu Mohindroo, Merve Hasanov, Jane E. Rogers, Wenli Dong, Laura R. Prakash, Seyda Baydogan, Jonathan D. Mizrahi, Michael J. Overman, Gauri R. Varadhachary, Robert A. Wolff, Milind M. Javle, David R. Fogelman, Michael T. Lotze, Michael P. Kim, Matthew H.G. Katz, Shubham Pant, Ching‐Wei D. Tzeng, Florencia McAllister

    Diterbitkan 2021-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience

    Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience oleh Manoop S. Bhutani, MD, FASGE, Irina M. Cazacu, MD, Alexandra A. Luzuriaga Chavez, MD, Ben S. Singh, BA, Franklin C.L. Wong, MD, William D. Erwin, MS, Eric P. Tamm, MD, Geena G. Mathew, MS, Dao B. Le, PharmD, Eugene J. Koay, MD, PhD, Cullen M. Taniguchi, MD, PhD, Bruce D. Minsky, MD, Shubham Pant, MD, Ching-Wei D. Tzeng, MD, Albert C. Koong, MD, PhD, Gauri R. Varadhachary, MD, Matthew H.G. Katz, MD, Robert A. Wolff, MD, David R. Fogelman, MD, Joseph M. Herman, MD

    Diterbitkan 2019-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: